Evidence map›Paper›PMID 34430591›Full record

ArticleAnnals of translational medicine2021

Novel ETV1 mutation in small cell lung cancer transformation resistant to EGFR tyrosine kinase inhibitors.

Yan Zhou, Hao Bai, Jinjing Xia, Wang-Yang Xu, Lei Cheng, Liwen Xiong

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Transcription factorBiomolecules & biomedicine · 2024
    Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Yan ZhouPulmonary and Critical Care Medicine Department, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Hao BaiPulmonary and Critical Care Medicine Department, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Jinjing XiaPulmonary and Critical Care Medicine Department, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Wang-Yang XuMedical Department, Singlera Genomics (Shanghai) Ltd., Shanghai, China.
Lei ChengPulmonary and Critical Care Medicine Department, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Liwen XiongPulmonary and Critical Care Medicine Department, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Shanghai Jiao Tong University · CNShanghai Chest Hospital · CNSinotech Genomics (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNon-small cell lung cancer (NSCLC) patients harboring mutations in the epidermal growth factor receptor (

methodsWe used a 639 cancer-relevant gene panel to detect genetic differences in tissues before and after

resultsWe present two

conclusionsNovel

Indexed as

drug resistanceEGFR tyrosine kinase inhibitor (EGFR TKI)ETV1non-small cell lung cancer (NSCLC)small cell lung cancer transformation (SCLC transformation)

Identifiers

PMID34430591
PMCPMC8350694
OpenAlexW3181500310

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.